GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic the action of glucagon-like peptide-1, a naturally occurring incretin hormone produced in the gut after eating. They bind to GLP-1 receptors throughout the body, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and acting on brain centers that regulate appetite and satiety [1]. Examples include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza). They were originally developed for type 2 diabetes but are now widely used for chronic weight management.

GLP-1 medications cause weight loss through several mechanisms: (1) they act on hypothalamic and brainstem receptors to reduce appetite and increase satiety, meaning you feel full sooner and eat less; (2) they slow gastric emptying, prolonging feelings of fullness after meals; (3) they modulate the brain's reward pathways, reducing cravings for high-calorie foods; and (4) there is emerging evidence suggesting improved lipid oxidation and metabolic rate in some patients [2]. The primary driver of weight loss is reduced caloric intake — clinical trial participants on semaglutide 2.4 mg consumed approximately 24–35% fewer calories compared to baseline [3].

Semaglutide is a GLP-1 receptor agonist that acts on a single target (the GLP-1 receptor). Tirzepatide is a dual agonist that activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism appears to provide enhanced effects on insulin sensitivity and body weight. In head-to-head trials (SURPASS-2), tirzepatide demonstrated superior glucose lowering compared to semaglutide 1 mg [4]. In the SURMOUNT-1 trial, tirzepatide at 15 mg achieved a mean weight loss of 22.5% at 72 weeks, compared to 16.9% for semaglutide 2.4 mg in STEP 1 at 68 weeks [5]. However, direct comparison is nuanced because these results come from different trials with different populations.

Based on available evidence, GLP-1 RAs have a favorable long-term safety profile. Semaglutide has been studied for up to 2 years in the STEP 5 trial with no new safety signals emerging beyond those identified in shorter studies [6]. The SELECT trial (17,604 participants, median follow-up 39.8 months) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with overweight/obesity and established cardiovascular disease, reinforcing its safety and cardiovascular benefit [7]. Tirzepatide safety data extend to 72 weeks from the SURMOUNT program. GLP-1 RAs have been available since 2005 (exenatide), providing nearly two decades of real-world safety data. Long-term monitoring should include regular assessment of pancreatic, thyroid, and renal function.

GLP-1 RAs carry a boxed warning regarding the risk of thyroid C-cell tumors based on findings in rodent studies. At clinically relevant doses, semaglutide and other GLP-1 RAs caused dose-dependent thyroid C-cell tumors in rats and mice. However, the relevance of these findings to humans is uncertain because rodents express significantly higher levels of GLP-1 receptors on thyroid C-cells than humans do [8]. Large observational studies and meta-analyses of clinical trial data have not demonstrated an increased risk of medullary thyroid carcinoma (MTC) in humans taking GLP-1 RAs. Nevertheless, these medications are contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [9]. Report any unusual neck swelling, dysphagia, or persistent hoarseness to your physician.

The most common side effects are gastrointestinal: nausea (30–44%), diarrhea (15–30%), vomiting (6–25%), and constipation (10–24%). These are typically mild-to-moderate, most prominent during dose escalation, and tend to diminish over time [10]. Management strategies include:

• Nausea: Eat smaller, more frequent meals; avoid fatty, greasy, or spicy foods; eat slowly; ginger tea or chews may help
• Constipation: Increase water intake, eat high-fiber foods, consider a stool softener or osmotic laxative (e.g., MiraLAX)
• Diarrhea: Stay hydrated, consider the BRAT diet during episodes, avoid dairy and high-fat foods temporarily
• Vomiting: Avoid lying down immediately after eating, eat bland foods, avoid overeating

If side effects are severe or persistent, your prescriber may recommend slowing the titration schedule. See our full Side Effects Guide for detailed management.

Acute pancreatitis has been reported in clinical trials and post-marketing surveillance of GLP-1 RAs, though it remains uncommon. In the STEP trials, pancreatitis occurred in <0.2% of semaglutide-treated patients [10]. A large meta-analysis of randomized controlled trials found no statistically significant increase in pancreatitis risk with GLP-1 RAs compared to placebo [11]. However, patients with a history of pancreatitis may be at higher risk and should use these medications with caution. Seek immediate medical attention if you experience severe, persistent abdominal pain radiating to the back, especially if accompanied by vomiting.

Any significant caloric deficit, regardless of cause, can lead to loss of lean body mass alongside fat mass. In the STEP 1 trial, approximately 40% of total weight lost was lean mass (60% fat mass) [12]. This proportion is typical for caloric-restriction-induced weight loss. To minimize muscle loss: prioritize protein intake (aim for 1.0–1.2 g per kg of body weight daily, or 25–30 g per meal), engage in regular resistance training (2–3 sessions per week), ensure adequate caloric intake (do not under-eat excessively), and consider creatine supplementation, which has strong evidence for preserving muscle mass during caloric deficit [13].

There is no absolute contraindication to alcohol with GLP-1 RAs, but caution is advised. Alcohol can worsen GI side effects (particularly nausea and vomiting), increase hypoglycemia risk (especially if you also take insulin or sulfonylureas), and impair judgment about food choices. Many patients report significantly reduced alcohol tolerance while on GLP-1 medications — one drink may feel like two or three. Interestingly, some research suggests GLP-1 RAs may reduce alcohol intake through modulation of reward pathways [14]. If you choose to drink, do so in moderation, eat before drinking, stay well hydrated, and avoid binge drinking. Monitor how you feel, as your tolerance may change.

For weekly injections (semaglutide, tirzepatide): If you miss your scheduled injection day, take the dose as soon as possible within 5 days. If more than 5 days have passed, skip the missed dose and take the next dose on your regular schedule. Do not double up on doses. You can change your injection day if needed — just ensure at least 48 hours between doses [15].

For daily injections (liraglutide): If you miss a dose, skip it and take your next dose at the regular time. Do not take a double dose to compensate.

If you frequently miss doses, consider setting a recurring phone alarm or associating the injection with a weekly routine (e.g., every Sunday morning).

Exercise is a critical complement to GLP-1 therapy, particularly for preserving lean mass. Guidelines recommend:

• Resistance training: 2–3 sessions per week targeting all major muscle groups. This is the single most important intervention for preserving muscle mass during weight loss [13].
• Aerobic exercise: 150–300 minutes per week of moderate-intensity activity (brisk walking, cycling, swimming) or 75–150 minutes of vigorous activity.
• Protein timing: Consume 20–30 g of protein within 1–2 hours of resistance training to maximize muscle protein synthesis.
• Start gradually: If you are new to exercise, begin with walking and light resistance exercises, progressively increasing intensity over weeks.

Note: some people experience reduced exercise capacity during early titration due to lower caloric intake. This typically resolves once you reach maintenance and adapt your eating patterns [16].

Protein intake is arguably the most critical dietary consideration while on GLP-1 medications. Because these drugs significantly reduce appetite, many patients unintentionally consume too little protein, accelerating lean mass loss. Current evidence-based recommendations for individuals on GLP-1 RAs:

• Minimum: 1.0 g protein per kg of body weight per day
• Optimal (if exercising): 1.2–1.6 g per kg per day
• Per meal: Aim for 25–30 g of protein at each meal
• Prioritize protein first: Start each meal with your protein source, as you may feel full before finishing everything on your plate

Good protein sources include poultry, fish, eggs, Greek yogurt, cottage cheese, legumes, tofu, and protein supplements if needed. A registered dietitian familiar with GLP-1 therapy can provide personalized guidance [17].

Current guidelines from the American Association of Clinical Endocrinology (AACE), the Endocrine Society, and the American Gastroenterological Association (AGA) recommend viewing obesity as a chronic disease requiring long-term treatment. Most patients will need to remain on GLP-1 therapy indefinitely to maintain weight loss. In the STEP 1 extension study, participants who discontinued semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year [18]. This weight regain is not a failure of willpower — it reflects the body's physiological adaptations (reduced metabolic rate, increased hunger hormones) that drive weight regain after loss. Some patients may be able to maintain on a lower dose. Discuss a long-term management plan with your prescriber.

Discontinuation of GLP-1 therapy typically results in gradual weight regain. The STEP 1 extension data showed that one year after stopping semaglutide 2.4 mg, participants regained an average of 11.6 percentage points of the 17.3% body weight they had lost (approximately two-thirds) [18]. Additionally, improvements in cardiometabolic parameters (blood pressure, lipids, HbA1c, waist circumference) also reversed. If you need to stop for medical reasons or access issues, work with your provider to develop a plan that includes dietary counseling, exercise optimization, and possible transition to alternative therapies.

GLP-1 receptor agonists are contraindicated during pregnancy. Animal studies with semaglutide showed adverse developmental effects including embryo-fetal mortality, structural abnormalities, and growth alterations. There are limited human data, but the potential risk to a developing fetus means GLP-1 RAs should be discontinued at least 2 months before a planned pregnancy (semaglutide has a half-life of approximately 1 week, and the recommendation is based on achieving 5+ half-lives of washout) [15]. If you become pregnant while on a GLP-1 medication, discontinue it immediately and contact your healthcare provider. GLP-1 RAs are also not recommended during breastfeeding due to insufficient safety data.

GLP-1 RAs can affect the absorption of other oral medications because they slow gastric emptying. Key interactions include:

• Oral contraceptives: Delayed absorption may reduce efficacy; barrier methods recommended during titration
• Insulin and sulfonylureas: Increased hypoglycemia risk; dose reduction of these medications may be needed
• Levothyroxine: Absorption may be delayed; monitor TSH levels
• Warfarin: Monitor INR closely, as absorption timing may change
• Oral antibiotics: Take 1 hour before the GLP-1 injection when possible

Inform all your healthcare providers that you are taking a GLP-1 RA. The delayed gastric emptying effect is most pronounced during early titration and may attenuate over time [19].

Insurance coverage for GLP-1 medications varies significantly. For diabetes indications (Ozempic, Mounjaro), most commercial insurance plans and Medicare Part D provide coverage. For weight management indications (Wegovy, Zepbound), coverage is more variable. As of 2026, many large employers have added anti-obesity medication coverage, and several states have passed laws requiring coverage. Medicare does not currently cover medications specifically for weight loss (though legislation is pending). Most plans require prior authorization, which may include documented BMI, previous weight loss attempts, and comorbidity documentation. See our Insurance Guide for detailed strategies.

Brand-name GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) are manufactured by pharmaceutical companies (Novo Nordisk, Eli Lilly) under strict FDA oversight, with guaranteed identity, purity, potency, and sterility. Compounded versions are produced by compounding pharmacies (503A for individual prescriptions, 503B for outsourcing facilities) using the same active ingredient (e.g., semaglutide base) but are NOT FDA-approved products [20]. FDA permits compounding of certain drugs when they are on the official drug shortage list. Key differences:

• Regulatory oversight: Brand = full FDA approval; Compounded = state pharmacy board + limited FDA oversight
• Cost: Brand = $900–$1,350/month without insurance; Compounded = typically $150–$500/month
• Form: Brand = pre-filled pens; Compounded = typically multi-dose vials requiring reconstitution or pre-mixed solutions
• Quality assurance: Brand = batch testing per cGMP; Compounded = variable, request COA from third-party lab

If using compounded products, verify the pharmacy is licensed, request Certificates of Analysis, and consult our COA Verification Guide.

Brand-name pens (unopened): Refrigerate at 36–46 °F (2–8 °C). Do not freeze. Protect from light. Check expiration date on packaging.

Brand-name pens (in use): Semaglutide pens can be stored at room temperature (up to 86 °F / 30 °C) for up to 56 days. Tirzepatide pens can be stored at room temperature for up to 21 days. Keep the cap on when not in use.

Compounded vials (reconstituted): Always refrigerate at 36–46 °F (2–8 °C). Use within 28–30 days of reconstitution. Never freeze reconstituted peptides, as this can degrade the protein. Minimize temperature fluctuations [15].

Traveling with injectable medications requires some planning:

• Air travel: Injectable medications with needles are permitted in carry-on luggage. Bring your prescription label or a letter from your prescriber. Inform TSA agents before screening.
• Temperature control: Use a medical-grade cooling case (such as Frio, MedActiv, or 4AllFamily) that maintains 2–8 °C without ice. Avoid checking your medication in luggage (cargo holds can freeze).
• Time zones: For weekly injections, adjust your injection day if crossing many time zones. A day early or late will not significantly affect efficacy.
• International travel: Carry your prescription documentation, keep medications in original packaging when possible, and research destination country regulations regarding injectable medications. Some countries may require additional documentation.
• Sharps disposal: Bring a portable sharps container. Many hotel front desks can assist with disposal if asked.

GLP-1 RAs are injected subcutaneously (into the fat layer under the skin) in one of three approved sites: the abdomen (at least 2 inches from the navel), the front of the thigh, or the upper arm (back/outer area). Absorption rates are generally similar across sites, though abdominal injections may be slightly faster [15]. Key injection tips:

• Rotate injection sites each week to prevent lipodystrophy (hardened fatty lumps)
• Allow refrigerated pens to reach room temperature for 30 minutes before injecting (reduces discomfort)
• Clean the site with an alcohol swab and let it dry
• Pinch the skin, insert the needle at a 90-degree angle, and hold for 5–10 seconds after injection
• Do not inject into areas that are bruised, tender, red, or scarred

Individual results vary significantly, but clinical trial averages provide a general benchmark:

• Semaglutide 2.4 mg (STEP 1): Mean weight loss of 14.9% (vs. 2.4% placebo) at 68 weeks. 32% of participants lost ≥20% body weight [1].
• Tirzepatide 15 mg (SURMOUNT-1): Mean weight loss of 22.5% (vs. 2.4% placebo) at 72 weeks. 36% lost ≥25% body weight [5].
• Liraglutide 3.0 mg (SCALE): Mean weight loss of 8.0% (vs. 2.6% placebo) at 56 weeks [21].

Factors affecting your results include starting BMI, adherence to titration schedule, dietary changes, exercise habits, metabolic rate, genetics, and concurrent medications. Some patients lose more than the average, and some less. Weight loss is typically most rapid in months 3–9 and plateaus around months 12–18.

Weight loss plateaus are normal and expected. After 12–18 months, the body reaches a new equilibrium where energy expenditure matches the reduced caloric intake. Strategies to consider:

• Verify you are at the optimal dose — if you have not titrated to the maintenance dose, discuss dose escalation with your prescriber
• Assess dietary patterns — caloric creep (gradually eating more over time) is common. Consider food tracking for 1–2 weeks
• Increase physical activity — add resistance training if not already doing so, or increase intensity/volume
• Check for metabolic adaptation — your provider may assess thyroid function, cortisol, and metabolic rate
• Evaluate sleep and stress — poor sleep and chronic stress increase cortisol, which promotes fat retention
• Patience — a plateau does not mean the medication has stopped working. It may be preventing regain even if the scale is not moving

Yes. The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE — cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 20% compared to placebo in 17,604 adults with established cardiovascular disease and overweight/obesity but without diabetes [7]. This was a landmark finding as it was the first trial to demonstrate cardiovascular benefit of an anti-obesity medication independent of diabetes. Additionally, the FLOW trial showed that semaglutide 1.0 mg reduced kidney disease progression and cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease [22]. Cardiovascular outcome data for tirzepatide are expected from the ongoing SURPASS-CVOT program.

Research increasingly suggests GLP-1 RAs may have benefits extending beyond glucose control and weight loss:

• Cardiovascular disease: Proven MACE reduction (SELECT trial) [7]
• Chronic kidney disease: Slowed progression (FLOW trial) [22]
• MASLD/MASH (fatty liver disease): Semaglutide demonstrated resolution of MASH without worsening fibrosis in 59% of treated patients vs. 17% placebo [23]
• Obstructive sleep apnea: Weight loss on semaglutide significantly reduced AHI scores (STEP-OSA trial)
• Heart failure with preserved ejection fraction: Improved symptoms and exercise capacity (STEP-HFpEF trial)
• Alcohol and substance use disorders: Preliminary evidence suggests reduced consumption (clinical trials underway)
• Polycystic ovary syndrome (PCOS): Improvements in hormonal profiles and fertility outcomes reported

Many of these applications are still under active investigation, and not all are currently approved indications.